Market Overview - The animal health sector experienced a decline of 0.53% on August 13, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - Key stocks in the animal health sector showed varied performance, with Xianfeng Holdings closing at 3.78, up 0.53%, and Dayu Biological closing at 9.84, down 3.15% [2][1] - Other notable stocks included Jinhe Biological at 7.45, down 3.12%, and Zhongmu Co. at 7.56, down 0.66% [2][1] Trading Volume and Value - The trading volume for Xianfeng Holdings was 268,700 shares with a transaction value of 102 million yuan, while Dayu Biological had a trading volume of 46,200 shares and a transaction value of 45.92 million yuan [2][1] Capital Flow Analysis - The animal health sector saw a net outflow of 175 million yuan from institutional investors, while retail investors contributed a net inflow of 143 million yuan [2][3] - The capital flow for specific stocks indicated that Hai Li Biological had a net inflow of 2.28 million yuan from institutional investors, while Xianfeng Holdings experienced a significant net outflow of 11.02 million yuan [3][2]

Core Viewpoint - Wuhan Keqian Biological Co., Ltd. plans to sign a cooperative research and development agreement with Huazhong Agricultural University, involving four vaccine projects, with a total payment of 4.9 million RMB [2][4][67]. Group 1: Overview of Related Transactions - The company has obtained cooperation for the development of four projects: "Canine Distemper, Canine Parainfluenza, Canine Adenovirus and Canine Parvovirus Quadrivalent Live Vaccine - Inactivated Canine Coronavirus Vaccine," "Porcine Gata Virus Inactivated Vaccine," "Porcine Proliferative Enteropathy Blocking ELISA Antibody Test Kit," and "NADC30-like Porcine Reproductive and Respiratory Syndrome Live Vaccine (GX2024 Strain)" [2][4][67]. - The total payment to Huazhong Agricultural University for these projects is 4.9 million RMB, with specific allocations of 1.5 million RMB, 2 million RMB, 400,000 RMB, and 1 million RMB for each project respectively [4][67]. - The transaction constitutes a related party transaction but does not qualify as a major asset restructuring under relevant regulations [2][4][67]. Group 2: Necessity and Impact of Related Transactions - The cooperative research aims to enhance the company's product portfolio and market competitiveness, although the success of the projects and their market introduction remain uncertain [67]. - The pricing and process of the transaction comply with legal regulations and do not harm the interests of the company or minority shareholders [67]. Group 3: Approval Procedures for Related Transactions - The board of directors and the supervisory board have approved the agreement, with related directors abstaining from voting [68][69]. - Independent directors have expressed that the agreement will enhance the company's core competitiveness in the biological products sector and that the transaction process is legal and fair [71][72]. Group 4: Research and Development Agreement Details - The agreement includes provisions for the rights and obligations of both parties, including the management of research funds and the ownership of intellectual property generated from the projects [8][37][52]. - The agreement is valid for 10 years, with provisions for extension and termination under certain conditions [20][36][66].

Core Viewpoint - The company has successfully completed the non-trading transfer of shares related to its 2025 employee stock ownership plan, with a total of 221.1573 million shares transferred at a price of 8 yuan per share, representing 0.4745% of the company's total share capital [3]. Group 1: Employee Stock Ownership Plan - The company held meetings on March 24, 2025, and April 11, 2025, where the 2025 employee stock ownership plan was approved, allowing for the implementation of the plan [2]. - A total of 55 employees participated in the stock ownership plan, contributing a total of 17.692584 million yuan, with the corresponding shares to be allocated [2]. - The duration of the employee stock ownership plan is set for 48 months, starting from the date of the last stock transfer to the plan's account [3]. Group 2: Share Transfer Details - The company has transferred 221.1573 million shares to the employee stock ownership plan's securities account, with the transfer price set at 8 yuan per share [3]. - The shares held in the employee stock ownership plan account will be subject to a lock-up period, which will be released upon meeting specific performance criteria [3]. - The company will continue to monitor the implementation of the employee stock ownership plan and fulfill its information disclosure obligations as required [3].

Core Viewpoint - The company plans to utilize idle raised funds for cash management, not exceeding RMB 260 million, to enhance fund efficiency while ensuring the normal operation of fundraising projects and maintaining fund safety [1][2][8] Summary by Sections Investment Purpose - The company aims to improve fund efficiency and increase shareholder returns by managing temporarily idle raised funds, ensuring it does not affect the progress of fundraising projects [5][7] Fund Source and Limit - The company will use up to RMB 260 million of idle raised funds for cash management, which can be rolled over within the specified limit [2][5] Investment Duration - The investment period is valid for 12 months from the date of the board's approval [5][6] Investment Method - The company will invest in high-security, liquid products such as structured deposits, time deposits, and large certificates of deposit, ensuring compliance with relevant regulations [5][6] Impact on Daily Operations - The cash management of idle funds will not affect the normal operation of fundraising projects and is expected to enhance overall performance and shareholder returns [7][8] Approval Process - The proposal for cash management has been approved by the board and supervisory board, complying with legal and regulatory requirements [8]

Core Viewpoint - The company plans to sign a cooperation research and development agreement with Huazhong Agricultural University, which is expected to enhance its core competitiveness in the bioproducts sector and accelerate its development in the industry [1]. Summary by Relevant Sections - **Cooperation Agreement**: The proposed agreement with Huazhong Agricultural University is seen as beneficial for improving the company's competitiveness in the bioproducts field [1]. - **Compliance and Procedures**: The transaction adheres to the company's articles of association, cooperation research and development management system, and the framework agreement with Huazhong Agricultural University, ensuring that all procedures are followed [1]. - **Related Party Transaction**: This transaction is classified as a related party transaction, with legal voting procedures and fair pricing, ensuring no harm to the company or its shareholders [1].

Summary of Key Points Core Viewpoint - The company intends to utilize idle raised funds for cash management to enhance fund efficiency and shareholder returns while ensuring that it does not affect the ongoing investment projects or the normal operations of the company [1][6]. Group 1: Fundraising and Usage - The company raised a total of RMB 1,227.45 million from its initial public offering (IPO) by issuing 105 million shares at a price of RMB 11.69 per share, with a net amount of RMB 1,141.73 million after deducting issuance costs of RMB 85.72 million [1][2]. - The total investment amount for the projects funded by the IPO is RMB 1,799.19 million, with RMB 1,747.03 million allocated from the raised funds [2]. - Due to a lower-than-expected net amount from the IPO, the company adjusted its investment projects, excluding certain projects and reallocating funds to ensure efficient use [2][3]. Group 2: Cash Management Plan - The company plans to use up to RMB 260 million of idle raised funds for cash management, ensuring that it does not impact the investment projects or the company's operations [3][5]. - The investment period for the cash management is valid for 12 months from the board's approval date, with a focus on low-risk, high-liquidity investment products [3][4]. - The income generated from cash management will be used to supplement any shortfall in the investment amounts for the projects and will be returned to the raised funds account upon maturity [4][6]. Group 3: Impact on Operations - The cash management of idle funds is expected to improve the efficiency of fund usage without affecting the normal progress of investment projects or the company's core business [4][6]. - By managing idle funds effectively, the company aims to achieve additional investment returns, thereby enhancing overall performance and providing greater returns to shareholders [4][6]. Group 4: Compliance and Approval - The cash management plan has been approved by the company's board and supervisory board, complying with relevant laws and regulations [5][6]. - The company will adhere to strict risk control measures and disclose information as required by regulatory authorities [4][6].

证券日报网讯 8月12日晚间，科前生物发布公告称，公司2025年8月12日召开第四届董事会第十三次会 议、第四届监事会第十二次会议审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司 使用额度不超过人民币26，000万元（含本数）的闲置募集资金在确保不影响募集资金投资项目进度、 不影响公司正常生产经营及确保资金安全的情况下进行现金管理，在上述额度范围内，资金可以滚动使 用，使用期限自公司董事会审议通过之日起12个月内有效。 （文章来源：证券日报） ...

Group 1 - The company, Keqian Bio, announced the approval of two significant proposals during the 12th meeting of its fourth supervisory board, including a cooperation research and development agreement with Huazhong Agricultural University and a related party transaction [1] - The company also approved a proposal to utilize idle raised funds for cash management purposes [1]

格隆汇8月12日丨科前生物(688526.SH)公布，在确保不影响募集资金投资计划正常进行、不影响公司正 常生产经营及确保资金安全的前提下,使用不超过人民币26,000万元（含本数）的闲置募集资金进行现金 管理。该等闲置募集资金在上述额度内可在投资期限内滚动使用。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 关联交易简要内容：武汉科前生物股份有限公司（下称"科 前生物"或"公司"）经与华中农业大学（下称"华中农大"）竞争 性谈判，取得了"犬瘟热、犬副流感、犬腺病毒与犬细小病毒病四联 活疫苗-犬冠状病毒病灭活疫苗"、"猪盖塔病毒灭活疫苗"、"猪 增生性肠炎阻断 ELISA 抗体检测试剂盒"、"类 NADC30 猪繁殖与呼 吸综合征活疫苗（GX2024 株）"四个项目的合作研发，现拟与华中 农大签订联合开发协议书，公司就以上四个研发项目一共需向华中农 大支付 490 万元人民币。合作研发项目产生的技术成果及知识产权归 公司及华中农大共同所有； 本次交易构成关联交易，不构成《上市公司重大资产重组管 理办法》规定的重大资产重组； 证券代码：688526 证券简称：科前生物 公告编号：2025-041 武汉科前生物股份有限公司 关于拟与华中农大签订合作研发协议暨关联交易的 自愿性披露公告 本次关联交易实施不存在重大法律障碍； 本次关联交易已经公司第四届董事会独立董事 20 ...